Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.

Beti-cel gene therapy shows durable safety, efficacy for transfusion-dependent β-thalassaemia

Audrey Abella
6 days ago

Long-term betibeglogene autotemcel (beti-cel) gene therapy led to durable, stable responses in patients with transfusion-dependent β-thalassaemia (TDT), according to two studies presented at ASH 2020.

Lifelong blood transfusions are the lifeline of TDT patients to improve haemoglobin (Hb) levels that drop due to β-globin gene mutations. However, transfusions inevitably lead to iron overload, which might subsequently progress to multi-organ damage. [Orphanet J Rare Dis 2010;5:11]

“The goal of beti-cel gene therapy in patients with TDT is lifelong, stable production of functional adult Hb sufficient for transfusion independence* (TI) and reduction in ineffective erythropoiesis,” said Dr Janet Kwiatkowski from the Children’s Hospital of Philadelphia, Pennsylvania, US, during the presentation of the LTF-303 results. “[Our findings] demonstrated the durability and stability of response after beti-cel gene therapy in [this patient setting].”

 

LTF-303 study

This 13-year follow-up analysis included data from four parent studies (two phase I/II [group 1] and two phase III studies [group 2]). After 2 years of follow-up, 32 patients (n=22 [group 1] and 10 [group 2) were enrolled. The results reported herein are based on those with follow-up data for up to 6 years. [ASH 2020, abstract 153]

Twenty-three patients achieved TI (n=14 [group 1] and 9 [group 2]) – two (from group 1) during follow-up and the rest during the parent studies. Weighted average Hb levels during TI were 10.4 and 12.5 g/dL in the respective groups 1 and 2. At last follow-up, all patients sustained TI for 39.4 months.

Gene therapy-derived Hb (HbAT87Q) in group 1 patients was stable at months 24, 36, 48, and 60 (6.4, 6.7, 6.6, and 7.1 g/dL, respectively). In group 2, median HbAT87Q was 9.5 g/dL at 24 months.

Pre-infusion, all participants were on iron chelation. Post-infusion, only 26 restarted iron chelation, but 11 discontinued. Seven patients (n=3 and 4 from groups 1 and 2, respectively) underwent phlebotomy for iron removal; three of whom were also on iron chelation.

“[The] sustained HbAT87Q levels and effective iron reduction with phlebotomy and/or iron chelation have resulted in improved haematologic parameters and iron burden,” said the researchers.

There were neither drug-product-related adverse events (AEs) >2 years post-infusion nor deaths, replication-competent lentivirus (RCL), or insertional oncogenesis. “The paucity of gene therapy-related AEs observed >2 years post-infusion study suggests a favourable long-term safety profile,” they added.

 

Similar responses in younger cohort

This interim evaluation focused on the expanded cohorts of the phase III Northstar 2 and 3 studies comprising 13 children (<12 years; n=8 [Northstar 2] and 5 [Northstar 3]) and 11 adolescents (≥12 to <18 years; n=6 and 5, respectively). [ASH 2020, abstract 154]

A total of 19 participants (n=12 and 7 from Northstar 2 and 3, respectively) with >3 months follow-up have stopped transfusions for ≥6 months.

In Northstar 2, three of four evaluable children and all adolescents achieved TI; at which point, weighted average Hb levels in these respective groups were 10.0 and 11.6 g/dL. At last visit, HbAT87Q were 5.1–7.1 and 8.4–10.5 g/dL, respectively.

In Northstar 3, one of two evaluable children and three evaluable adolescents achieved TI. Weighted average Hb levels during TI were 10.3 g/dL (children) and 9.6 g/dL (adolescents), and HbAT87Q at last visit were 9.2 and 8.0–10.9 g/dL, respectively.

“[These suggest] that, after treatment with beti-cel, paediatric patients <18 years achieved TI with comparable rates as in adults, suggesting that beti-cel gene therapy represents an effective treatment option across ages,” said Dr Alexis Thompson from the Ann & Robert H Lurie Children’s Hospital of Chicago, Illinois, US, who presented the findings.

The most frequent post-infusion nonhaematologic grade ≥3 AEs in either study were febrile neutropenia, stomatitis, and decreased appetite (children), and stomatitis, febrile neutropenia, and hypoxia (adolescents). Veno-occlusive disease occurred in one child (grade 2) and two adolescents (grade 4), which were successfully managed with defibrotide.

“Neither RCL, insertional oncogenesis, nor clonal dominance were observed … The safety profile of gene therapy with beti-cel was consistent with busulfan myeloablation,” added Thompson and colleagues.

In both LTF-303 and paediatric studies, autologous CD34+ cells were transduced with BB305 lentiviral vector containing a modified human β-globin gene to produce the beti-cel drug product, and infused after a single-agent, pharmacokinetic-adjusted busulfan myeloablation.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.